Impact of Surgical Strategy on Perioperative Outcomes, Time to Adjuvant Chemotherapy, and Quality of Life in Malignant Colon Obstruction: A Nationwide Prospective Multicenter Cohort Study
Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background. Malignant colon obstruction is a surgical emergency, and the operating surgeon often has to choose an operative strategy quickly under unfavourable physiological conditions. Whether the choice between primary anastomosis, resection with stoma, combined anastomosis with diverting stoma, or diverting stoma alone influences perioperative outcomes and the interval to adjuvant chemotherapy is still unclear. We addressed these questions in a national prospective cohort and also followed health-related quality of life (HRQoL) over the first postoperative year. Methods. Patients undergoing surgery for malignant colon obstruction were enrolled across 13 tertiary centers in Türkiye (NCT05429060). Standardized perioperative data were collected, and HRQoL was assessed with the EORTC QLQ-CR29 instrument preoperatively and at 3 and 12 months. Outcomes were compared across the four surgical strategies using one-way ANOVA for continuous variables and the χ² or Fisher–Freeman–Halton exact test for categorical variables. Time to chemotherapy was analyzed both as a continuous variable and dichotomized at a 30-day threshold. Results. Of 174 patients enrolled, 165 met inclusion criteria (mean age 65.4 ± 13.1 years; 54.5% male). Resection with primary anastomosis was most common (50.3%), followed by resection with stoma (24.8%), combined anastomosis with stoma (13.3%), and diverting stoma without resection (11.5%). Advanced-disease markers—metastasis, perforation, carcinomatosis, and peritonitis—were significantly more frequent in the diverting-stoma and resection-with-stoma groups (all p ≤ 0.012). Operation time differed markedly across techniques (84.7 to 207.6 minutes; p < 0.001), whereas postoperative complications (35.2% overall), reoperation (6.1%), and early mortality (9.7%) did not differ significantly. Adjuvant chemotherapy was initiated in 68.5% of patients at a mean of 29.1 ± 15.8 days; neither the mean interval (p = 0.194) nor the rate of delay beyond 30 days (p = 0.646) differed by surgical strategy. HRQoL scores improved from baseline to 12 months across symptom and functional domains, without significant between-technique differences at any timepoint. Conclusions. In malignant colon obstruction, the surgical strategy reflects disease severity and operative complexity, but is not independently associated with the timing of adjuvant chemotherapy or with medium-term quality of life. Diverting stoma without resection was linked to numerically earlier chemotherapy, most likely because of the lower physiological burden rather than a causal advantage. Individualised decision-making and close multidisciplinary coordination remain central to optimising outcomes. Trial registration ClinicalTrials.gov NCT05429060.
Source: Research Square
Authors: Atif Tekin, Metin Kement, Serhat Meriç, Nihat Bugdayci, Erkan Yavuz, Rozan Kaya, Ensar Çakır, Mert Mahsuni Sevinç, Ufuk Oğuz İdiz, Kıvılcım Ulusan, Alp Ömer Cantürk, Yusuf Bilgin, Erkan Somuncu, Hakan Yırgın, Yunus Emre Altuntaş, Mehmet Karahan, Selçuk Kaya, Noyan İlhan, Aytaç Emre Kocaoğlu, Naciye Çiğdem Arslan, Osman Civil, Mehmet Ali Gök, Mustafa Celalettin Haksal, Ömer Faruk Özkan, Nurhilal Kızıltoprak, Berkay Özcan, İlknur Turan, Ercan Gedik, Abdülkadir Akbaş, Hakan Kul, Fevzi Cengiz, Hüseyin Esin, Tayfun Kaya, Levent Uğurlu, Semra Salimoğlu, Erdinç Kamer, Murat Çakır, Mustafa Öncel
Institutions: Istanbul Medipol University, Bağcılar Eğitim ve Araştırma Hastanesi, İstanbul Eğitim ve Araştırma Hastanesi, İstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi, Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi, Ümraniye Eğitim ve Araştırma Hastanesi, Dicle University, Izmir Kâtip Çelebi University, Izmir Tepecik Eğitim ve Araştırma Hastanesi, Necmettin Erbakan University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funder: İstanbul Medipol Üniversitesi
OpenAlex ID: W7236861585
